Clinical trials: Cartilage Injury
Cartilage Injury of Knee
A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
This is a Phase 2, double-blind, multicenter, randomized, placebo-controlled trial to evaluate the efficacy and safety of Sprifermin (AS902330) (recombinant human fibroblast growth factor-18 [rhFGF-18]) as an adjunct treatment to…
- Trial name
- NCT01689337
- Testing
- Sprifermin (AS902330)
- Volunteers
- 1 people
- Sponsor
- EMD Serono
Isolated Cartilage Injury of the Knee
Sprifermin (AS902330) in Cartilage Injury Repair (CIR)
Several people all over the world suffer from cartilage injuries in the knee. Symptoms include pain, joint swelling, and loss of function. Without repair, cartilage injury may ultimately lead to osteoarthritis (OA).
- Trial name
- NCT01066871
- Testing
- Sprifermin (AS902330) 10 mcg, Sprifermin (AS902330) 30 mcg, Sprifermin (AS902330) 100 mcg
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- Merck KGaA, Darmstadt, Germany